Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Werewolf Therapeutics, Inc. - Common Stock (NQ:HOWL)

0.6472 +0.0050 (+0.78%)

Streaming Delayed Price Updated: 10:52 AM EST, Jan 7, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	43,221
Open	0.6588
Bid (Size)	0.6472 (2,000)
Ask (Size)	0.6500 (300)
Prev. Close	0.6422
Today's Range	0.6472 - 0.6598
52wk Range	0.5588 - 2.380
Shares Outstanding	27,567,728
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Top movers in Thursday's session ↗

December 18, 2025

Stay up-to-date with the latest market trends one hour before the close of the markets on Thursday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

Keep an eye on the top gainers and losers in Thursday's session. ↗

December 18, 2025

Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements.

Via Chartmill

Performance

YTD	+0.4%	+0.4%
1 Month	-35.3%	-35.3%
3 Month	-66.5%	-66.5%
6 Month	-38.9%	-38.9%
1 Year	-60.0%	-60.0%

More News

There are notable gap-ups and gap-downs in today's session. ↗

December 18, 2025

Via Chartmill

One Patient's Complete Response to Investigational Cancer Therapy Sparks Hope

August 14, 2025

Via Brandpoint

Werewolf Therapeutics Announces Pipeline and Business Updates

December 18, 2025

From Werewolf Therapeutics, Inc.

Via GlobeNewswire

Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting

November 07, 2025

From Werewolf Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 05, 2025

Via Benzinga

Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

November 04, 2025

From Werewolf Therapeutics, Inc.

Via GlobeNewswire

Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer

October 08, 2025

From Werewolf Therapeutics, Inc.

Via GlobeNewswire

Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting

October 03, 2025

From Werewolf Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

September 23, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

September 22, 2025

Via Benzinga

Curious about the stocks that are showing activity after the closing bell on Monday? ↗

September 22, 2025

Via Chartmill

Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference

September 02, 2025

From Werewolf Therapeutics, Inc.

Via GlobeNewswire

Werewolf Reports No Revenue in Fiscal Q2 ↗

August 14, 2025

Via The Motley Fool

Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

August 14, 2025

From Werewolf Therapeutics, Inc.

Via GlobeNewswire

Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit

July 09, 2025

From Werewolf Therapeutics, Inc.

Via GlobeNewswire

Werewolf Therapeutics to Participate in the BIO International Convention

June 12, 2025

From Werewolf Therapeutics, Inc.

Via GlobeNewswire

Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference

May 29, 2025

From Werewolf Therapeutics, Inc.

Via GlobeNewswire

Top movers in Tuesday's after hours session ↗

May 20, 2025

Via Chartmill

HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124

May 20, 2025

From Werewolf Therapeutics, Inc.

Via GlobeNewswire

Werewolf Therapeutics to Participate in Hanson Wade’s 6th Annual Cytokine-Based Drug Development Summit

May 13, 2025

From Werewolf Therapeutics, Inc.

Via GlobeNewswire

Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 08, 2025

From Werewolf Therapeutics, Inc.

Via GlobeNewswire

Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting

May 05, 2025

From Werewolf Therapeutics, Inc.

Via GlobeNewswire

Werewolf Therapeutics to Participate in Upcoming Investor Conferences

May 05, 2025

From Werewolf Therapeutics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Werewolf Therapeutics, Inc. - Common Stock publicly traded?

Yes, Werewolf Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Werewolf Therapeutics, Inc. - Common Stock trade on?

Werewolf Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Werewolf Therapeutics, Inc. - Common Stock?

The ticker symbol for Werewolf Therapeutics, Inc. - Common Stock is HOWL on the Nasdaq Stock Market

What is the current price of Werewolf Therapeutics, Inc. - Common Stock?

The current price of Werewolf Therapeutics, Inc. - Common Stock is 0.6472

When was Werewolf Therapeutics, Inc. - Common Stock last traded?

The last trade of Werewolf Therapeutics, Inc. - Common Stock was at 01/07/26 10:52 AM ET

What is the market capitalization of Werewolf Therapeutics, Inc. - Common Stock?

The market capitalization of Werewolf Therapeutics, Inc. - Common Stock is 17.84M

How many shares of Werewolf Therapeutics, Inc. - Common Stock are outstanding?

Werewolf Therapeutics, Inc. - Common Stock has 18M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.